Literature DB >> 33765515

A free mailed naloxone program in Philadelphia amidst the COVID-19 pandemic.

Rachel French1, Jamie Favaro2, Shoshana V Aronowitz3.   

Abstract

BACKGROUND: Access to naloxone is essential as the overdose crisis persists. We described barriers to accessing naloxone among individuals who requested and received the medication from a free mailed program and explored the relationship between how individuals with and without personal proximity to overdose learned about the program.
METHODS: Secondary analysis of data from a web-based form collected 1st March 2020 to 31st January 2021. Access barriers, personal proximity to overdose (broadly defined as personally overdosing or witnessing/worrying about others overdosing), and method of learning about the program were categorized and described.
RESULTS: Among 422 respondents, the most frequently reported barriers to accessing naloxone were: COVID quarantine (25.1%), lack of knowledge about access (13.2%), and cost (11.2%). Compared to those without personal proximity to overdose (38.2%), individuals with personal proximity (61.8%) heard about the program more often through an active online search (21.4% vs. 8.8%; p-value = 0.001) and less often through word of mouth (19.8% vs. 40.9%; p-value = <0.001).
CONCLUSIONS: Longstanding barriers to naloxone access are compounded by the COVID-19 pandemic, making mailing programs especially salient. Differences in ways that individuals with and without personal proximity to substance use and overdose learned about this program can inform how such programs can effectively reach their target audience.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Harm reduction; Naloxone; Opioid overdose

Mesh:

Substances:

Year:  2021        PMID: 33765515      PMCID: PMC8373681          DOI: 10.1016/j.drugpo.2021.103199

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  14 in total

1.  Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states.

Authors:  Traci C Green; Patricia Case; Haley Fiske; Janette Baird; Shachan Cabral; Dina Burstein; Victoriana Schwartz; Nathan Potter; Alexander Y Walley; Jeffrey Bratberg
Journal:  J Am Pharm Assoc (2003)       Date:  2017-02-14

2.  Ethical Imperatives to Overcome Stigma Against People With Substance Use Disorders.

Authors:  Jerome M Adams; Nora D Volkow
Journal:  AMA J Ethics       Date:  2020-08-01

3.  People, places, and stigma: A qualitative study exploring the overdose risk environment in rural Kentucky.

Authors:  Monica Fadanelli; David H Cloud; Umedjon Ibragimov; April M Ballard; Nadya Prood; April M Young; Hannah L F Cooper
Journal:  Int J Drug Policy       Date:  2019-11-18

4.  NEXT Harm Reduction: An Online, Mail-Based Naloxone Distribution and Harm-Reduction Program.

Authors:  Carol Yang; Jamie Favaro; Meredith C Meacham
Journal:  Am J Public Health       Date:  2021-02-18       Impact factor: 9.308

5.  Opioid Use Disorder and COVID-19: Crashing of the Crises.

Authors:  Utsha G Khatri; Jeanmarie Perrone
Journal:  J Addict Med       Date:  2020 Jul/Aug       Impact factor: 3.702

6.  Availability and Cost of Naloxone Nasal Spray at Pharmacies in Philadelphia, Pennsylvania, 2017.

Authors:  Jenny S Guadamuz; G Caleb Alexander; Tanya Chaudhri; Rebecca Trotzky-Sirr; Dima M Qato
Journal:  JAMA Netw Open       Date:  2019-06-05

7.  Intersecting U.S. Epidemics: COVID-19 and Lack of Health Insurance.

Authors:  Steffie Woolhandler; David U Himmelstein
Journal:  Ann Intern Med       Date:  2020-04-07       Impact factor: 25.391

8.  Stigma as a fundamental hindrance to the United States opioid overdose crisis response.

Authors:  Alexander C Tsai; Mathew V Kiang; Michael L Barnett; Leo Beletsky; Katherine M Keyes; Emma E McGinty; Laramie R Smith; Steffanie A Strathdee; Sarah E Wakeman; Atheendar S Venkataramani
Journal:  PLoS Med       Date:  2019-11-26       Impact factor: 11.069

9.  Racial/Ethnic and Age Group Differences in Opioid and Synthetic Opioid-Involved Overdose Deaths Among Adults Aged ≥18 Years in Metropolitan Areas - United States, 2015-2017.

Authors:  Kumiko M Lippold; Christopher M Jones; Emily O'Malley Olsen; Brett P Giroir
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-11-01       Impact factor: 17.586

10.  HaRePo (harm reduction by post): an innovative and effective harm reduction programme for people who use drugs using email, telephone, and post service.

Authors:  Magally Torres-Leguizamon; Emmanuel G Reynaud; Thomas Néfau; Catherine Duplessy
Journal:  Harm Reduct J       Date:  2020-08-24
View more
  3 in total

1.  The impact of COVID-19 on people who inject drugs in New York City: increased risk and decreased access to services.

Authors:  Yesenia Aponte-Melendez; Pedro Mateu-Gelabert; Chunki Fong; Benjamin Eckhardt; Shashi Kapadia; Kristen Marks
Journal:  Harm Reduct J       Date:  2021-11-24

Review 2.  Illicit Substance Use and the COVID-19 Pandemic in the United States: A Scoping Review and Characterization of Research Evidence in Unprecedented Times.

Authors:  Anh Truc Vo; Thomas Patton; Amy Peacock; Sarah Larney; Annick Borquez
Journal:  Int J Environ Res Public Health       Date:  2022-07-21       Impact factor: 4.614

3.  "We have to be uncomfortable and creative": Reflections on the impacts of the COVID-19 pandemic on overdose prevention, harm reduction & homelessness advocacy in Philadelphia.

Authors:  Shoshana V Aronowitz; Eden Engel-Rebitzer; Margaret Lowenstein; Zachary Meisel; Evan Anderson; Eugenia South
Journal:  SSM Qual Res Health       Date:  2021-09-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.